Product Program year 2019 Source: CMS Open Payments

MacRilen

Drug Growth Hormone

NDC 71090-002-02

Open in the dashboard

General payments

$23,270

717 payments

Research payments

$0

0 payments

Through program year 2019, $23,270 in general payments and $0 in research payments were reported against MacRilen (Growth Hormone).

No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.

By program year

1 row
Year Kind Amount Payments
2019 General $23,270 717

Breakdown

Who paid General payments · program year 2019
  1. Novo Nordisk Inc $23,270 717 payments
Top recipients General payments · program year 2019
  1. Stephen Usala Endocrinology, Diabetes & Metabolism · Amarillo, TX $970 4% · 5 payments
  2. Richard Griffiths Endocrinology, Diabetes & Metabolism · Little Rock, AR $880 4% · 3 payments
  3. Saleemah Fahmi Endocrinology, Diabetes & Metabolism · Dallas, TX $773 3% · 3 payments
  4. Kenny Brantley Endocrinology, Diabetes & Metabolism · Amarillo, TX $732 3% · 4 payments
  5. Anthony Heaney Endocrinology, Diabetes & Metabolism · Los Angeles, CA $388 2% · 6 payments

The top 5 of the 100 largest recipients; each share is of general payments naming this product in 2019.

The top 25 recipients, free in the app

Specialties paid General payments · program year 2019
  1. Endocrinology, Diabetes & Metabolism Internal Medicine $17,239 75% · 318 practitioners
  2. Pediatric Endocrinology Pediatrics $1,919 8% · 63 practitioners
  3. Family Medicine $777 3% · 15 practitioners
  4. Internal Medicine $773 3% · 22 practitioners
  5. Pulmonary Disease Internal Medicine $384 2% · 2 practitioners

The top 5 of 34 specialties; each share is of general payments naming this product to practitioners with a specialty in 2019. Each practitioner is counted under their primary specialty.

The top 25 specialties, free in the app

Where the money went General payments · program year 2019
  1. Texas $4,546 20% · 41 recipients
  2. Ohio $1,952 8% · 47 recipients
  3. California $1,543 7% · 26 recipients
  4. Michigan $1,528 7% · 42 recipients
  5. Washington $1,274 5% · 7 recipients

The top 5 of 42 states; each share is of general payments naming this product in 2019 where a state was reported.

The top 25 states, free in the app

717 general

Every payment, record by record

Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.

What you are looking at

Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.

Provenance

Source: CMS Open Payments · through program year 2019

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record